SynAct Pharma comments on ownership changes among senior executives
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SynAct Pharma AB (publ) ("SynAct") comments on changes in ownership among senior executives in the company. GoodWind Holding GmbH with registered office in Baar / Switzerland (GoodWind) has decided to distribute SynAct shares as dividend to the respective owners, which has resulted in insider registration for several of the SynAct's senior executives.
At the Annual General Assembly of GoodWind, on 21 March 2024, the shareholders in GoodWind decided to distribute dividends for the fiscal year 2023. The dividends were distributed in the form of SynAct shares (SYNACT) at the value at market closing at the Nasdaq Stockholm on 21 March 2024. In total 977,256 shares were distributed.
In a separate transaction Boesen Biotech ApS, owned by Thomas Boesen, COO of SynAct, is purchasing shares from GoodWind, generating proceeds to cover GoodWind’s tax obligations in relation to the distribution of dividends. Owners of GoodWind includes Boesen Biotech ApS (COO Thomas Boesen), GL Capital AB (Torbjörn Bjerke, former CEO), Quantass ApS (Jeppe Øvlesen, CEO), and TJ Biotech Holding ApS (Thomas Jonassen, CSO). GoodWind’s holding in SynAct amounted to 1,161,777shares on the day of the decision by the AGM.
For further information, please contact:
CEO Jeppe Øvlesen
Tel: +45 2844 7567
Email: joo@synactpharma.com
About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolving activity to help patients achieve immune balance and overcome their inflammation. For more information, please contact: www.synactpharma.com.